DoW Breast Cancer, Clinical Research Extension Award
🏛 Defense Health Agency Contracting Activity - DHACA (DOD-AMRAA)
✓ Free, no account · Source: Grants.gov · Last verified Oct 30, 2026
Can you apply?
This grant is for academic, medical, and clinical research institutions conducting breast cancer clinical studies. Applicants must have a Principal Investigator with relevant breast cancer research experience. The research team must include two or more breast cancer consumer advocates. Projects may have a single PI or two partnering PIs. This is a national program open to U.S. institutions conducting clinical research that extends existing studies.
Not the right fit? Find grants for your organization in 5 questions →
Key dates
- Aug 20, 2026 Applications open
- Nov 18, 2026 Application deadline in 18 days
- Sep 30, 2027 Award announced
- Sep 30, 2027 Project start
Program description
Summary: The fiscal year 2026 (FY26) Breast Cancer Research Program (BCRP) Clinical Research Extension Award supports research that extends the data collection, follow-up, and analysis of breast cancer clinical studies. The intent of this award mechanism is to increase the clinically relevant impact of breast cancer patient participation in clinical studies by addressing the knowledge lost due to early trial termination, limited patient follow-up, or suboptimal sample and/or data collection and analysis. All applications must address at least one of the FY26 BCRP overarching challenges or provide adequate justification for exception.
Distinctive Features:
• The research team must include two or more breast cancer consumer advocates.
• This funding mechanism allows for a single Principal Investigator (PI), or two partnering PIs referred to as the Initiating PI and the Partnering PI. For the Partnering PI Option (PPIO), only the Initiating PI will submit a pre-application, but both PIs will need to submit at the full application stage. Be advised, failure to submit all associated (Initiating and Partnering PI) applications by the deadline may result in administrative withdrawal.
Who can apply
Eligible applicants
How to apply
Application links
Key dates & requirements
Required documents
- Pre-application (if using Partnering PI Option)
- Full project narrative
- Budget and budget justification
- Biographical sketches (PI and key personnel)
- Consumer advocate documentation and role descriptions
- Evidence of institutional support/commitment
- Letters of support from collaborating institutions (if applicable)
Program contact
- 👤 eBRAP Help Desk Phone: 301-682-5507 Email: help@eBRAP.org
- 📧 help@eBRAP.org
- 📞 301-682-5507
Funding track record
Recent awards under CFDA 12.420 from the last 3 years — real organizations that won funding through this same program.
Top 10 Largest Recent Awards
-
$2,265,729,366
-
$800,456,231
-
$77,591,450
-
$74,531,880
-
$55,949,967
-
$34,191,124
-
$24,783,894
-
$21,394,379
-
$19,100,256
-
$19,002,641
Top States by Funding
- MD 10 awards $3,149.9M
- NC 11 awards $132.3M
- CA 14 awards $121.2M
- MA 12 awards $110.3M
- FL 8 awards $99.8M
Source: USAspending.gov — federal spending transparency. Data covers last 3 years.
Funding history
Annual funding for this program — Federal obligations (CFDA 12.420). How funding has trended year over year.
| 2024 | $1,483,968,520 | |
| 2025 | $1,201,153,417 |
FAQ
Can a single PI submit this application?
Yes. You may submit with one PI, or alternatively pursue the Partnering PI Option with two PIs. Both options are supported.
What does "clinical research extension" mean?
This award extends ongoing clinical studies through additional data collection, follow-up, and analysis. It addresses data loss from early termination or incomplete patient follow-up.
Are consumer advocates required?
Yes. Your research team must include at least two breast cancer consumer advocates as active participants.
What is the deadline structure?
The deadline is fixed at November 18, 2026. Pre-applications are required before full applications for the Partnering PI Option.
What funding range should I expect?
The total program pool is $8.4 million. Individual award amounts vary based on project scope and review outcomes.
💡 Tips for applicants
- Include at least two breast cancer consumer advocates as active, named team members with defined roles in your research plan.
- If using the Partnering PI Option, both PIs must submit full applications by the deadline, or both may face administrative withdrawal.
- Address at least one FY26 BCRP overarching challenge or provide strong justification for any exceptions.
- Emphasize how your extension will increase clinically relevant impact and recover data that would otherwise be lost.
- Clearly document the existing clinical study, its current status, and specific gaps your extension will address.
⚠️ Common mistakes
Missing or insufficient consumer advocate involvement. Applications may be rejected if advocates are listed but lack clear roles or decision-making power. Failure to submit all partnering PI applications by deadline triggers automatic administrative withdrawal. Insufficient justification for not addressing an FY26 BCRP overarching challenge.
Similar grants
- OPEN DoW Breast Cancer, Breakthrough Award Levels 1 and 2 — Defense Health Agency Contracting Activity - DHACA
- OPEN DoW Rare Cancers Resource and Community Development Award — Defense Health Agency Contracting Activity - DHACA
- CLOSING SOON DoW Bone Marrow Failure, Investigator-Initiated Research Award — Defense Health Agency Contracting Activity - DHACA
- OPEN DoW Toxic Exposures Clinical Trial Award — Defense Health Agency Contracting Activity - DHACA
- OPEN DoW Toxic Exposures Translational Research Award — Defense Health Agency Contracting Activity - DHACA